Adaptimmune Therapeutics PLC Corporate Call Transcript
Good morning. I'm Adrian Rawcliffe, Adaptimmune's CEO, and thank you for joining us. I refer you to our disclaimer. More details can be found in the press release we issued earlier this morning. I'm delighted to be introducing this new data from our SURPASS trial and our plans for the SURPASS family of trials. This data set confirms the power of our SPEAR T-cells to make a difference for patients. It identifies multiple tumor types for further development, and it continues our leadership position making T cells effective against solid tumors.
But before we get into that, I want to provide a little background on Adaptimmune and our technology. For those of you who are perhaps less familiar with Adaptimmune, we engineer T cells to fight cancer, empowering a person's own immune system against their disease. Our unique technology platform enables us to enhance the affinity of T cell receptors, or TCRs. T cells use TCRs to see targets on cells. If a target is recognized as alien, the T cell will kill
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
